about
A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System TargetsAdvancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesStructure-Based Statistical Mechanical Model Accounts for the Causality and Energetics of Allosteric CommunicationEmerging Computational Methods for the Rational Discovery of Allosteric Drugs.Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.AlloPred: prediction of allosteric pockets on proteins using normal mode perturbation analysis.Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled ReceptorsIntegrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsProteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.Harnessing allostery: a novel approach to drug discovery.The role of structural disorder in cell cycle regulation, related clinical proteomics, disease development and drug targeting.Biophysics: for HTS hit validation, chemical lead optimization, and beyond.Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands.Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild TypeAllosterism in human complement component 5a ((h)C5a): a damper of C5a receptor (C5aR) signaling.The effect of introducing small cavities on the allosteric inhibition of phosphofructokinase from Bacillus stearothermophilusAsymmetric configurations in a reengineered homodimer reveal multiple subunit communication pathways in protein allostery.Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites.Toward Understanding "the Ways" of Allosteric DrugsAn allosteric modulator to control endogenous G protein-coupled receptors with light.Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening.Molecular function of α7 nicotinic receptors as drug targets.Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.GABAA receptors activate fish feeding behaviour via two distinct functional pathways.Implementation of the NMR CHEmical Shift Covariance Analysis (CHESCA): A Chemical Biologist's Approach to Allostery.Identifying Protein Allosteric Transitions for Drug Discovery with 1D NMR.Druggable negative allosteric site of P2X3 receptors.An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy.Allosteric binding sites in Rab11 for potential drug candidates.Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response.
P2860
Q26781471-5D7B65E7-AE3E-4533-A68F-AF2344EDD2A0Q26829985-2DC35E34-7A96-49ED-A80D-5B82D86710E8Q28550501-010A3455-02A0-47B9-8CB3-58FF75C4ED2EQ30358225-BEC538DC-8D8B-4B05-9B4E-B4AC4CD4DE75Q33574533-3903FF54-ABFB-4FFC-B7CC-880FBEC39275Q34243209-11E4D4A3-6FEA-4387-8FD0-938446462ECAQ34399823-672B8157-F84F-458C-B16D-687BCC478AF3Q35817816-AAEB704B-D29E-4803-AFFB-5AE3A6DEF077Q35967903-1AAF246B-F32A-420D-9C90-F197D6EC480DQ36385771-C37ED180-3295-460F-BFA1-0FF714085874Q36389619-5469B6E2-9066-40BB-BE59-ECA0D86E1C55Q37183072-F5CD87F2-6EC8-416E-A3CC-CB19BD754A81Q37575496-96D63191-96E0-4F76-94C6-4102FFA4CCE8Q38211688-98FB1C9F-0DC2-4ABC-BACC-7F6548A9A41DQ38481133-6E92C617-524E-4977-8250-2967C8976D62Q38665514-4BB2C213-1508-4965-87C5-F7DF95F284D1Q38761171-41AFACC4-A340-4014-81A3-9FC6BF57DB08Q38842676-7CD8AC9D-9475-49BF-9708-DCFBFD4A23E8Q38973739-B4A06AA6-2008-44C5-9E38-67AA911B4779Q40435465-F675FF9D-2472-4204-8F0F-DACD1FE9551AQ40695140-DDB5EA64-FEE5-4C62-AA9C-C5777EA65716Q41632958-2B079B2D-14A4-4F5C-8049-562A32669DF2Q41840924-E8906E82-9568-450D-906D-AF38BEB25849Q42047360-D9910C9B-ABCB-4164-BD5D-7A29FA8878CFQ42367157-E03C3376-E940-4FE6-B266-9AC6BBD70691Q42704321-CC1D5695-32B5-4598-BF58-C1E2BDFADE63Q47279853-F5662034-C898-487A-900B-0107AE4B7C7AQ47409603-709D4ABC-36BC-446F-A14F-3DD7AE21A8E2Q48001582-2BE6BA76-A51A-457B-82FB-25D853A83100Q48207669-0364D812-87BA-4BCD-B46D-0BFFE4EBE53DQ49904697-0EED229D-2B1D-47CC-93AF-CADAE16ADA04Q51110047-F64F3D71-132D-4351-8F6D-A54BACF4F32DQ52576591-C1980E33-E19A-4210-8B51-23B66516FC3CQ52684505-8326D503-595A-4B37-BB7F-D7997A33E66EQ55281306-AC683F00-261B-44D5-ACD7-C67D49BEDFAAQ55449469-F8F42434-6E29-48FB-89AC-C96C7B9272E6
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Drugs for allosteric sites on receptors
@ast
Drugs for allosteric sites on receptors
@en
Drugs for allosteric sites on receptors
@nl
type
label
Drugs for allosteric sites on receptors
@ast
Drugs for allosteric sites on receptors
@en
Drugs for allosteric sites on receptors
@nl
prefLabel
Drugs for allosteric sites on receptors
@ast
Drugs for allosteric sites on receptors
@en
Drugs for allosteric sites on receptors
@nl
P2860
P3181
P1476
Drugs for allosteric sites on receptors
@en
P2093
Craig W Lindsley
Thomas P Mathews
P2860
P304
P3181
P356
10.1146/ANNUREV-PHARMTOX-010611-134525
P407
P577
2013-10-02T00:00:00Z